Atai Life Sciences is making incremental progress towards opening door for a first psychedelic treatment for depression. Read ...

Industry veteran Catherine Owen Adams expects external innovation will be key to getting the brain-focused drug developer to “the next level.” ...

Life Sciences & Beckley Psytech announce positive results from phase 2b study of BPL-003 in patients with treatment-resistant depression: New York Wednesday, July 2, 2025, 10 ...

None have been approved by the Food and Drug Administration so far, though in 2019, Johnson & Johnson received FDA permission ...

Positive study results in Phase 2 lead to a green light for the companies’ combination and plans to move their nasal spray ...

Cosmo Feilding Mellen – currently Beckley's chief executive, who is slated to serve as chief strategy officer of the merged ...

A psychedelic nasal spray requiring a much shorter period of clinical supervision has shown promise against ...

Atai Life Sciences’ psychedelic drug has successfully reduced the symptoms of depression in a phase 2 study, triggering the next stage of the biotech’s planned merger with mental health company ...

Ketamine has been making headlines for years, from the death of actor Matthew Perry to Elon Musk's reported microdosing, to its portrayal in Hulu's "The Secret Lives of Mormon Wives." ...

Bay Psychiatric Associates is excited to announce a successful Open House event at its newly expanded San Mateo location, ...

A drug used for Parkinson's disease has been shown to be effective in reducing the symptoms of difficult to treat depression, ...